The Evolution of Gene Therapy in Sickle Cell Disease: Milestones, Mechanisms, and Market Trends
Main Article Content
Abstract
Sickle Cell Disease (SCD), a debilitating hereditary blood disorder, has long posed significant therapeutic challenges due to its genetic origin and systemic complications. Recent advancements in gene therapy have revolutionized the treatment landscape, offering curative potential by targeting the disease at its molecular root. This study examines the evolution, mechanisms, and market trends of three major gene therapy approaches: gene addition using lentiviral vectors, gene editing via CRISPR-Cas9 technology, and fetal hemoglobin (HbF) reactivation through BCL11A disruption. Through a comprehensive analysis of clinical outcomes, regulatory approvals, and implementation feasibility, the study reveals that gene editing offers the highest therapeutic efficacy, while HbF reactivation provides a more accessible and scalable solution, particularly in low-resource settings. Market data indicate growing interest and regulatory momentum, but high treatment costs and infrastructure barriers remain critical obstacles. The findings underscore the need for innovative, cost-effective gene therapy platforms and inclusive policy frameworks to ensure equitable access to these life-saving treatments across diverse global populations.